Login / Signup

Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis.

Francesco Del GiudiceRocco Simone FlammiaBenjamin I ChungMarco MoschiniBenjamin PradereAndrea MariFrancesco SoriaSimone AlbisinniWojciech KrajewskiTomasz SzydełkoEkaterina LaukhtinaDavid d'AndreaAndrea GallioliLaura S MertensMartina MaggiAlessandro SciarraStefano SalcicciaMatteo FerroCarlo Maria ScornajenghiVincenzo AseroSusanna CattarinoMario De AngelisGiovanni E CacciamaniRiccardo AutorinoSavio Domenico PandolfoUgo Giovanni FalagarioNicola D'AltiliaVito ManciniMarco ChiricoFrancesco CinelliCarlo BettocchiLuigi CormioGiuseppe CarrieriEttore De BerardinisGian Maria Busettonull On Behalf Of European Association Of Urology Eau-Young Academic Urologists Yau Urothelial Cancer Working Party
Published in: Cancers (2022)
When routinely performing re-TUR followed by a maintenance BCG schedule, TICE was superior to RIVM for RFS outcomes. However, no significant differences were detected for PFS and CSS, respectively.
Keyphrases
  • muscle invasive bladder cancer
  • early stage
  • metabolic syndrome
  • adipose tissue
  • glycemic control